Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-22
2008-04-22
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C546S193000, C546S232000, C544S162000, C514S318000, C514S322000
Reexamination Certificate
active
07361655
ABSTRACT:
The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions containing the carboxamidine derivatives of the invention, and the use thereof for the treatment of vascular diseases and in the preparation of pharmaceutical compositions for the treatment of vascular diseases.
REFERENCES:
patent: 4187220 (1980-02-01), Takacs et al.
patent: 4404384 (1983-09-01), Gebert et al.
patent: 4451286 (1984-05-01), Martin et al.
patent: 5147879 (1992-09-01), Nagy et al.
patent: 5239077 (1993-08-01), Bertok et al.
patent: 5278309 (1994-01-01), Bertok et al.
patent: 5296606 (1994-03-01), Nagy et al.
patent: 5328906 (1994-07-01), Nagy et al.
patent: 5334600 (1994-08-01), Van Duzer et al.
patent: 6649628 (2003-11-01), Kurthy et al.
patent: 6653326 (2003-11-01), Vigh et al.
patent: 7126002 (2006-10-01), Urogdi et al.
patent: 7148239 (2006-12-01), Vigh et al.
patent: 2059184 (1992-07-01), None
patent: 0369944 (1990-05-01), None
patent: 1540028 (1979-02-01), None
patent: 1582029 (1980-12-01), None
patent: WO 90/04584 (1990-05-01), None
patent: WO 90/08131 (1990-07-01), None
patent: WO 92/03130 (1992-03-01), None
patent: WO 95/30649 (1995-11-01), None
patent: WO 97/00251 (1997-01-01), None
patent: WO 97/13504 (1997-04-01), None
patent: WO 97/16439 (1997-05-01), None
patent: WO 9716439 (1997-05-01), None
patent: WO 98/06400 (1998-02-01), None
patent: WO 98/43948 (1998-10-01), None
patent: WO 00/35914 (2000-06-01), None
patent: WO 00/50403 (2000-08-01), None
patent: WO 01/79174 (2001-10-01), None
patent: WO 2005/041965 (2005-05-01), None
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).
DeKoning, et al., “Org. 2766 improves Functional and Electrophysical Aspects of Regenerating Sciatic Nerve in the Rat,”Peptides, 8(3):415-422, (1987).
Morrison, et al.,Organic Chemistry, Allyn and Bacon, Inc. (Boston), 205-211, (1983).
Sorensen H. and Mortensen K., “Soluble expression of recombinant proteins in the cytoplasm ofEscherichia coli,” Microbial Cell Factories, 4:1-8(2005).
Stanley, “Sensory and Motor Nerve Conduction Velocities and the Latency of the H-Reflex During Growth of the Rat,”Experimental Neurology, 71(2):497-506, (1981).
Tesfamariam, et al., “Contraction of Diabetic Rabbit Aorta Caused by Endothelium-Derived PGH2-TxA2,”American Journal of Physiology, 257(5):1327-1333, (1989).
Winslow, et al., “Comparative Effects of the Isomers of Bepridil on Isolated Coronary and Aortic Arteries,”European Journal of Pharmacology, 166(2):241-249, (1989).
Burger, Alfred, “Pro-Drugs,”A Guide to the Chemical Basis of Drug Design, p. 15, 1.3.1, 1983.
“Preparation and Spectral Study of O-methyl=benzamidoximes,” Beltrao et al., Chemical Abstracts, 89:215038s (1978).
Csákai Zita Jegesné
Dénes László
Márványos Ede
Török Magdolna Bathóné
Ürögdi László
Cytrx Corporation
Habte Kahsay T
Ropes & Gray LLP
Ruskin Barbara A.
LandOfFree
Pharmaceutically effective compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutically effective compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically effective compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747497